Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Zimran

Showing results (201-210 of 238) with videos related to

Pageof 24
Sort By:
American Journal of Hematology|February 7, 2013
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 studyDerlis E Gonzalez, Hadhami Ben Turkia, Elena A Lukina, et al.
American Journal of Hematology|November 2, 2017
Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)Ari Zimran, Nadia Belmatoug, Bruno Bembi, et al.
The American Journal of Medicine|July 23, 2002
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryNeal J Weinreb, Joel Charrow, Hans C Andersson, et al.
International Journal of Molecular Sciences|October 27, 2022
A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease-Identifying Those at the Greatest RiskMichal Becker-Cohen, Ari Zimran, Tama Dinur, et al.
Thrombosis and Haemostasis|September 10, 2021
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher DiseaseShoshana Revel-Vilk, Mira Naamad, Dafna Frydman, et al.
Journal of Clinical Medicine|April 14, 2026
Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical StudiesAri Zimran, Jaco Botha, Richard Eastell, et al.
Molecular Genetics and Metabolism|December 28, 2010
Pyrimethamine increases β-hexosaminidase A activity in patients with Late Onset Tay SachsEtty Osher, Aviva Fattal-Valevski, Liora Sagie, et al.
Blood Cells, Molecules & Diseases|June 22, 2014
A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imigluceraseGregory M Pastores, Milan Petakov, Pilar Giraldo, et al.
Blood Cells, Molecules & Diseases|June 9, 2009
The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause)Ari Zimran, Elizabeth Morris, Eugen Mengel, et al.
Life (Basel, Switzerland)|June 26, 2025
Prodromal Parkinsonian Features in Carriers of Gaucher Disease Compared to ControlsMichal Becker-Cohen, Ari Zimran, Tama Dinur, et al.
Pageof 24

Showing results (201-210 of 238) with videos related to

Sort By:
Pageof 24
American Journal of Hematology|February 7, 2013
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 studyDerlis E Gonzalez, Hadhami Ben Turkia, Elena A Lukina, et al.
American Journal of Hematology|November 2, 2017
Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)Ari Zimran, Nadia Belmatoug, Bruno Bembi, et al.
The American Journal of Medicine|July 23, 2002
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryNeal J Weinreb, Joel Charrow, Hans C Andersson, et al.
International Journal of Molecular Sciences|October 27, 2022
A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease-Identifying Those at the Greatest RiskMichal Becker-Cohen, Ari Zimran, Tama Dinur, et al.
Thrombosis and Haemostasis|September 10, 2021
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher DiseaseShoshana Revel-Vilk, Mira Naamad, Dafna Frydman, et al.
Journal of Clinical Medicine|April 14, 2026
Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical StudiesAri Zimran, Jaco Botha, Richard Eastell, et al.
Molecular Genetics and Metabolism|December 28, 2010
Pyrimethamine increases β-hexosaminidase A activity in patients with Late Onset Tay SachsEtty Osher, Aviva Fattal-Valevski, Liora Sagie, et al.
Blood Cells, Molecules & Diseases|June 22, 2014
A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imigluceraseGregory M Pastores, Milan Petakov, Pilar Giraldo, et al.
Blood Cells, Molecules & Diseases|June 9, 2009
The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause)Ari Zimran, Elizabeth Morris, Eugen Mengel, et al.
Life (Basel, Switzerland)|June 26, 2025
Prodromal Parkinsonian Features in Carriers of Gaucher Disease Compared to ControlsMichal Becker-Cohen, Ari Zimran, Tama Dinur, et al.
Pageof 24